[
  {
    "ts": null,
    "headline": "Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight",
    "summary": "The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed.",
    "url": "https://finnhub.io/api/news?id=6fdd21760a3d9cddf4caa3409f50674a1cbfac444dcdba2abccc6b56310ee9cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765492260,
      "headline": "Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight",
      "id": 137766873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed.",
      "url": "https://finnhub.io/api/news?id=6fdd21760a3d9cddf4caa3409f50674a1cbfac444dcdba2abccc6b56310ee9cd"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript",
    "summary": "Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call December 11, 2025 9:00 AM ESTCompany ParticipantsKate BenderCristian Massacesi - Executive VP,...",
    "url": "https://finnhub.io/api/news?id=9aacc615683acfb0e758b14abeb6f31b0b665dd6e8607a44de811a580c3b832f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765477971,
      "headline": "Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript",
      "id": 137762938,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call December 11, 2025 9:00 AM ESTCompany ParticipantsKate BenderCristian Massacesi - Executive VP,...",
      "url": "https://finnhub.io/api/news?id=9aacc615683acfb0e758b14abeb6f31b0b665dd6e8607a44de811a580c3b832f"
    }
  },
  {
    "ts": null,
    "headline": "Acute Lymphocytic Leukemia Market: Analysis and Forecast, 2025-2035",
    "summary": "The global acute lymphocytic leukemia (ALL) market is set for substantial growth from 2025 to 2035, fueled by advances in chemotherapy, targeted therapies, and immunotherapy. Particularly affecting children and aggressive in adults, ALL is increasingly treated with personalized medications like Tyrosine Kinase Inhibitors and CAR-T cell therapy, transforming patient outcomes. Despite challenges like high treatment costs and drug resistance, the demand for innovative combination therapies is risin",
    "url": "https://finnhub.io/api/news?id=94c1c45cc2af17a21c2dacb57fb1db49c3e9274659e702d94952c231888b9ca3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765471080,
      "headline": "Acute Lymphocytic Leukemia Market: Analysis and Forecast, 2025-2035",
      "id": 137758862,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The global acute lymphocytic leukemia (ALL) market is set for substantial growth from 2025 to 2035, fueled by advances in chemotherapy, targeted therapies, and immunotherapy. Particularly affecting children and aggressive in adults, ALL is increasingly treated with personalized medications like Tyrosine Kinase Inhibitors and CAR-T cell therapy, transforming patient outcomes. Despite challenges like high treatment costs and drug resistance, the demand for innovative combination therapies is risin",
      "url": "https://finnhub.io/api/news?id=94c1c45cc2af17a21c2dacb57fb1db49c3e9274659e702d94952c231888b9ca3"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call - Slideshow",
    "summary": "2025-12-11. The following slide deck was published by Bristol-Myers Squibb Company in conjunction with this event.",
    "url": "https://finnhub.io/api/news?id=e72e5e77e410ce043a65edc2dca52d422496d9f5a65efb68b60e0cfa53c3fc49",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765454465,
      "headline": "Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call - Slideshow",
      "id": 137759061,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "2025-12-11. The following slide deck was published by Bristol-Myers Squibb Company in conjunction with this event.",
      "url": "https://finnhub.io/api/news?id=e72e5e77e410ce043a65edc2dca52d422496d9f5a65efb68b60e0cfa53c3fc49"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma",
    "summary": "PRINCETON, N.J., December 11, 2025--US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma",
    "url": "https://finnhub.io/api/news?id=a5bf138f87f11fc91cce08b0fdfc3e6da7db78d7c71536b4de24eb6af665ee9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765454340,
      "headline": "U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma",
      "id": 137757044,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., December 11, 2025--US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma",
      "url": "https://finnhub.io/api/news?id=a5bf138f87f11fc91cce08b0fdfc3e6da7db78d7c71536b4de24eb6af665ee9c"
    }
  },
  {
    "ts": null,
    "headline": "3 Unpopular Stocks with Questionable Fundamentals",
    "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
    "url": "https://finnhub.io/api/news?id=f3a275275921d0f07bf77b15ca759a8acee3439eead12cbccfc54def30dc36a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765427766,
      "headline": "3 Unpopular Stocks with Questionable Fundamentals",
      "id": 137758037,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
      "url": "https://finnhub.io/api/news?id=f3a275275921d0f07bf77b15ca759a8acee3439eead12cbccfc54def30dc36a5"
    }
  }
]